Sotac Pharma Live Share Price Today, Share Analysis and Chart

About the company - Business Profile

Sotac Pharmaceuticals Ltd (SOTAC) is an India-based pharmaceutical company that specializes in manufacturing a diverse range of pharmaceutical formulations. The company primarily operates through a business model focused on Contract Development and Manufacturing Organizations (CDMO) and third-party manufacturing services, catering to domestic and international clients.

Key Points

• Key Facts: Founded in 2015, Sotac Pharmaceuticals is headquartered in Ahmedabad, Gujarat. The company is listed on the NSE Emerge platform. Its core business includes the production of tablets, capsules, and various other dosage forms.
• Operations and Resources: The company operates manufacturing facilities located in Sanand, Ahmedabad, which are compliant with WHO-GMP standards. These facilities are equipped to handle large-scale production across multiple therapeutic segments.
• Ownership: The company is promoter-led, with the promoter group maintaining a significant majority stake.
• Market and Significance: Sotac serves as a critical manufacturing partner for several established pharmaceutical brands in India. Its strategic importance lies in its ability to provide cost-effective manufacturing solutions for both generic and branded formulations.
• Sustainability and Innovation: The company focuses on operational efficiency and compliance with environmental standards. While detailed long-term environmental metrics are limited, the company emphasizes continuous process improvement to reduce waste in its manufacturing cycles.

Business Model and Financials

Sotac Pharmaceuticals' business model is centered on its proficiency in large-scale formulation manufacturing. It is particularly strong in the Oral Solid Dosage (OSD) segment and has been expanding its capabilities in specialized delivery systems.

Revenue Breakdown by Segment (Annual FY2024-25 Estimates): The company derives a substantial portion of its revenue from the domestic market through contract manufacturing.

• Tablets and Capsules (OSD): This segment remains the primary revenue driver, contributing to a significant majority of total sales.
• Other Formulations: Includes syrups, ointments, and specialized medical products.

Financial Performance Highlights (FY 2024-25):

• Income from Operations: The company reported consolidated income from operations of approximately Rs. 19,831.85 Lakhs for FY 2024-25, compared to Rs. 15,437.25 Lakhs in the previous year.
• Net Profit After Tax: Consolidated PAT for the year ending March 31, 2025, reached Rs. 3,115.69 Lakhs.
• Growth Trends: The OSD segment witnessed a growth of 10.73% year-on-year, while general injectables grew by 6.06%. A notable surge was seen in the Ophthalmic segment, which grew by 70.96% due to increased demand and doubled manufacturing capacity at its plants.

Strategic Initiatives and Outlook

• Capacity Expansion: The company is currently executing a Greenfield pharmaceutical project at Khopoli, Maharashtra. This facility is intended to broaden the product portfolio and enhance Sotac's presence in international markets.
• Diversification: Sotac is actively moving into higher-margin segments like Ophthalmic and Cephalosporin products. The Cephalosporin segment recorded a 28.04% growth in FY 2024-25.
• Partnerships: The company maintains strong relationships with mid-to-large cap pharmaceutical companies, acting as an outsourced manufacturing partner.
• Future Outlook: Management is focused on scaling operations through the completion of its ongoing Capex cycle. The strategic goal is to leverage increased capacity to target regulated markets and high-growth therapeutic areas.